MyFinsight
Home
Blog
About
Contact
Download
Download image
Belbuca
$221,653K
(4.92%↑ Y/Y)
Xtampza ER
$199,308K
Jornay Pm
$148,857K
(299.73%↑ Y/Y)
Nucynta IR
$115,312K
(14.46%↑ Y/Y)
Nucynta ER
$80,985K
Symproic And Other
$14,452K
Product revenues, net
$780,567K
(23.62%↑ Y/Y)
Gross profit
$463,257K
(22.77%↑ Y/Y)
Total cost of product
revenues
$317,310K
(24.87%↑ Y/Y)
Income from operations
$179,636K
(5.73%↑ Y/Y)
Interest income
$11,289K
(-19.23%↓ Y/Y)
Total operating
expenses
$283,621K
(36.72%↑ Y/Y)
Gain on fair value
remeasurement of contingent...
-$1,182K
(59.44%↑ Y/Y)
Intangible asset
amortization
$221,892K
Cost of product
revenues (excluding...
$95,418K
(7.45%↑ Y/Y)
Income before income
taxes
$92,619K
(-6.04%↓ Y/Y)
Interest expense
$82,312K
(11.27%↑ Y/Y)
Loss on
extinguishment of debt
-$15,994K
(-41.18%↓ Y/Y)
Selling, general and
administrative
$284,803K
(35.39%↑ Y/Y)
Net income
$62,870K
(-9.13%↓ Y/Y)
Provision for income taxes
$29,749K
(1.26%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
COLLEGIUM PHARMACEUTICAL, INC (COLL)
COLLEGIUM PHARMACEUTICAL, INC (COLL)